Patel Naimish sold $211K of CRSP
Patel Naimish (Chief Medical Officer) sold 3,786 shares of CRISPR Therapeutics AG (CRSP) at $55.62 ($0.21M total) on 2026-05-29.
How this was made
The 30-second read
Why it matters
This provides a datapoint on insider behavior but does not introduce new clinical, regulatory, or financial information.
Market read
Traders may monitor for follow-on insider activity, but the filing alone is unlikely to be a primary driver of price.
What to watch
No 10b5-1 plan is cited, but the article provides no reason for the sale, tax context, or whether other insiders executed offsetting trades.
Background
The article is an SEC Form 4 insider transaction disclosure for CRISPR Therapeutics (CRSP).
Ticker impact
CRSP’s CMO Patel Naimish sold 3,786 shares in an open-market transaction disclosed via SEC Form 4 on 2026-05-29.
Likely limited immediate impact; any reaction would be sentiment-driven rather than fundamental.
The filing is an officer open-market sale with no stated link to new clinical/regulatory or financial developments; 10b5-1 plan is explicitly marked as not pre-arranged, but insider sales alone rarely drive durable repricing without corroborating news.
Market effects
Minimal; this is company-specific insider activity with no disclosed sector-wide catalyst.
None indicated beyond US-listed biotech sentiment.
None indicated.
Counterpoint
The sale may be routine liquidity/portfolio rebalancing rather than a bearish view, especially given the small absolute size versus typical insider holdings.
Key entities
- issuerCRISPR Therapeutics AG
Subject of the SEC Form 4 insider sale disclosure.
- insiderPatel Naimish
Chief Medical Officer who sold shares via open-market sale.
